<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118374</url>
  </required_header>
  <id_info>
    <org_study_id>190630</org_study_id>
    <nct_id>NCT04118374</nct_id>
  </id_info>
  <brief_title>A Pilot Study to Determine Iatrogenic Hyperinsulinemia's Contribution to Insulin Resistance and Endothelial Dysfunction in Type 1 Diabetes</brief_title>
  <official_title>A Pilot Study to Determine Iatrogenic Hyperinsulinemia's Contribution to Insulin Resistance and Endothelial Dysfunction in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will test the hypothesis that reducing insulin doses using a low
      carbohydrate diet (LCD) will be associated with with improved insulin sensitivity (Aim 1) and
      blood vessel health (Aim 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin resistance (IR) is consistently found in patients with type 1 diabetes (T1DM) and
      pathophysiologically links T1DM with atherosclerotic disease. IR and nascent atherosclerosis,
      as characterized by endothelial dysfunction, are present early in T1DM. Although
      atherosclerosis leads to cardiovascular disease (CVD)—the predominant cause of death in
      T1DM—the early cardiometabolic processes driving atherosclerosis are not currently
      well-characterized. My overarching hypothesis is that IR and endothelial dysfunction in T1DM
      are, in part, iatrogenic, occurring as a function of nonphysiologic insulin delivery.

      Previous research shows IR in T1DM is closely related to iatrogenic hyperinsulinemia.
      Iatrogenic hyperinsulinemia in T1DM results from injecting insulin into subcutaneous tissue
      rather than delivering insulin more physiologically into the hepatic portal vein.
      Hyperinsulinemia, per se, is closely linked with IR and independently predicts CVD in
      diabetic and nondiabetic populations. Thus, peripheral insulin delivery brings about
      unintended adverse cardiometabolic consequences in T1DM. The investigators propose a
      practical intervention to diminish iatrogenic hyperinsulinemia and thereby mitigate CVD risk.
      The investigators hypothesize that a reduction in iatrogenic hyperinsulinemia brought about
      by a low carbohydrate diet (LCD) will independently correlate with improved insulin
      sensitivity (Aim 1) and endothelial function (Aim 2).

      In this pilot study, the investigators will mechanistically dissect the contribution of
      iatrogenic hyperinsulinemia to IR and endothelial dysfunction in 8 adults with T1DM using a
      crossover study of LCD vs. standard carbohydrate diet (SCD) to experimentally modify
      hyperinsulinemia. The investigators will quantify insulin sensitivity using hyperinsulinemic,
      euglycemic clamps and measure endothelium-dependent flow mediated vasodilation using
      high-resolution ultrasound.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in insulin sensitivity - diet 1</measure>
    <time_frame>baseline to 1 week</time_frame>
    <description>Change in insulin sensitivity based on diet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin sensitivity - diet 2</measure>
    <time_frame>baseline to 1 week</time_frame>
    <description>Change in insulin sensitivity based on diet</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in endothelial function - diet 1</measure>
    <time_frame>baseline to 1 week</time_frame>
    <description>will quantify brachial artery, endothelium-dependent flow-mediated vasodilation using high-resolution ultrasound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in endothelial function - diet 2</measure>
    <time_frame>baseline to 1 week</time_frame>
    <description>will quantify brachial artery, endothelium-dependent flow-mediated vasodilation using high-resolution ultrasound</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Standard Carb Diet then Low Carb Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Carb Diet then Standard Carb Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Carb Diet</intervention_name>
    <description>Approximately 50% of caloric intake will come from carbohydrate consumption.</description>
    <arm_group_label>Low Carb Diet then Standard Carb Diet</arm_group_label>
    <arm_group_label>Standard Carb Diet then Low Carb Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Carb Diet</intervention_name>
    <description>Approximately 25% of caloric intake will come from carbohydrate consumption.</description>
    <arm_group_label>Low Carb Diet then Standard Carb Diet</arm_group_label>
    <arm_group_label>Standard Carb Diet then Low Carb Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-60

          -  HbA1c: 5.9-9.0%

          -  Insulin delivery: must be on an insulin pump

          -  Glucose Monitor: must use a continuous glucose monitor (CGM)

          -  BMI 18-28 kg/m^2

          -  Body Mass &gt;/= 50 kg ( 110 lbs)

        Exclusion Criteria:

          -  severe hypoglycemia : &gt;/= 1 episode in the past 3 months

          -  diabetes comorbidities (&gt;= 1 trip to emergency department for poor glucose control in
             the past 6 months,

          -  New York Heart Association Class II-IV cardiac functional status

          -  SBP &gt; 140 and DBP &gt; 100 mmHg,

          -  eGFR by MDRD equation of &lt;60 mL/min/1.73m^2

          -  AST or ALT &gt; 2.5 times the upper limit of normal

          -  HCT &lt;35%

        medications

          -  any antioxidant vitamin supplement (&lt;2 weeks before STUDY visit)

          -  any systemic glucocorticoid

          -  any antipsychotic

          -  atenolol, metoprolol, propranolol

          -  niacin

          -  any thiazide diuretic

          -  any OCP with &gt; 35 mcg ethinyl estradiol,

          -  growth hormone

          -  any immunosuppressant

          -  any antihypertensive

          -  any antihyperlipidemic

        other:

          -  pregnancy

          -  Tanner stage &lt; 5

          -  peri or postmenopausal woman

          -  active smoker

          -  gluten-free diet requirement

        Additional exclusion criteria for T1DM subjects

          -  any diabetes medication except insulin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin M Gregory, MD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tyler J Smith, BSN</last_name>
    <phone>6159366324</phone>
    <email>metabolism@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tyler J Smith, BSN</last_name>
      <phone>615-478-5987</phone>
      <email>metabolism@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Justin M Gregory, MD, MSCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>October 4, 2019</last_update_submitted>
  <last_update_submitted_qc>October 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Justin Gregory</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>low carbohydrate diet</keyword>
  <keyword>hyperinsulinemia</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>vascular health</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperinsulinism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The datasets generated during and/or analyzed during the current study can be available from the corresponding author upon reasonable request. Data sets can be made available beginning 3 months and ending 5 years following article publication. No applicable resources have yet been generated or analyzed during the current study.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

